• Dissecting Drug Response in Cancer: Innovations in In Vitro

  2026-05-15

  Schwartz's dissertation critically advances our understanding of how anti-cancer drug effects are measured in vitro, distinguishing between growth arrest and cell death. By elucidating the nuanced relationship between relative and fractional viability, this work sets a new standard for evaluating compounds like tyrosine kinase inhibitors in oncology research.

• Torin2: Redefining mTOR Inhibition for Translational Oncolog

  2026-05-15

  This article delivers a strategic, mechanistic, and workflow-driven perspective on the advanced mTOR inhibitor Torin2. By integrating up-to-date mechanistic insights, evidence from apoptosis research, and practical guidance for translational researchers, the discussion frames Torin2 not just as a reagent, but as a pivotal tool for uncovering new dimensions of mTOR-driven oncogenesis and therapeutic intervention. The narrative spotlights recent paradigm shifts in cell death signaling, details best-practice experimental parameters, and positions Torin2 at the forefront of next-generation cancer research.

• Cyclic di-GMP: Applied Workflows for Biofilm & Immunity Rese

  2026-05-14

  Cyclic di-GMP enables researchers to dissect biofilm persistence and immune signaling with precision, acting as both an intracellular second messenger and STING pathway agonist. This guide translates the latest mechanistic insights into actionable protocols, troubleshooting, and advanced cross-domain applications—empowering infection biology and cancer immunotherapy studies.

• RepSox (ALK5 Inhibitor): Optimizing iPSC Platelet Differenti

  2026-05-14

  RepSox, a potent ALK5 inhibitor from APExBIO, is transforming induced pluripotent stem cell (iPSC) workflows by enhancing platelet production yield and cost-effectiveness. Discover how strategic protocol refinements and troubleshooting can unlock new applications in regenerative medicine and cell therapy.

• Dissecting Cognitive Processes in Rodent Depression Tests vi

  2026-05-13

  Li et al. (2025) introduce computational modeling and fine-grained behavioral tracking to parse the cognitive underpinnings of rodent forced swim and tail suspension tests. Their approach distinguishes learning and consequence sensitivity as dynamic drivers of behavior, challenging assumptions about test interchangeability and refining the analysis of depression-like phenotypes.

• N1-Methylpseudouridine: Enabling Next-Gen mRNA Translation

  2026-05-13

  Explore how N1-Methylpseudouridine, a leading modified nucleoside, drives mRNA translation enhancement with reduced immunogenicity. This article offers unique, protocol-focused insights for practical assay design and translational research.

• Tivozanib (AV-951): Precision VEGFR Inhibition in Oncology R

  2026-05-12

  Tivozanib (AV-951) delivers unparalleled selectivity and potency for VEGFR signaling pathway inhibition, empowering oncology researchers to model anti-angiogenic therapy with confidence. This article details robust workflows, practical troubleshooting, and advanced applications that maximize the translational impact of Tivozanib in renal cell carcinoma and beyond.

• Orientia tsutsugamushi Alters RIPK3 Levels Without Blocking

  2026-05-12

  This study reveals that Orientia tsutsugamushi, the agent of scrub typhus, reduces host cell RIPK3 levels but does not inhibit necroptosis once triggered. These findings clarify distinct pathogen-host strategies for modulating programmed cell death and have implications for the broader understanding of cell death pathways in infection biology.

• JNJ-10198409: Precision PDGF Receptor Inhibition for Tumor a

  2026-05-11

  Discover how JNJ-10198409, a potent platelet-derived growth factor receptor inhibitor, enables advanced research into tumor growth and fibrotic disorders. This article explores its unique mechanism, protocol guidance, and the translational insights it brings to PDGF-driven disease models.

• AR and ARv7 in TNBC: Prognostic Roles and EPI-001 Modulation

  2026-05-11

  This study elucidates the prognostic significance of androgen receptor (AR) and ARv7 expression in triple-negative breast cancer (TNBC), linking both to poor outcomes and increased metastasis. Targeted inhibition of AR/ARv7—particularly with the N-terminal domain inhibitor EPI-001—demonstrates suppression of metastatic and EMT markers, indicating new strategies for AR-driven TNBC intervention.

• RapaLink-1: Redefining mTOR Inhibition in Dormancy & Oncolog

  2026-05-10

  This thought-leadership article explores how RapaLink-1, a third-generation mTOR inhibitor from APExBIO, is transforming the landscape of translational research in both oncology and embryonic dormancy. It integrates mechanistic insight, protocol guidance, and strategic perspectives, leveraging new evidence on reversible stem cell dormancy through mTOR inhibition. The discussion bridges cancer biology with developmental protocols, highlighting RapaLink-1’s unique role in overcoming resistance, enabling scalable noninvasive assays, and setting the stage for future translational breakthroughs.

• Pharmacokinetic Variability of CSBTA in MASH Mouse Models

  2026-05-09

  This study systematically investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. By identifying the roles of CYP450 enzymes, transporters, and the pregnane X receptor (PXR) in mediating these effects, the work provides critical guidance for optimizing dosage regimens in MASLD/MASH research and therapy.

• 5-hme-dCTP: Advanced Platform for DNA Hydroxymethylation Map

  2026-05-08

  Explore the scientific and practical advances of 5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate) for high-resolution epigenetic DNA modification research. This article delivers unique, method-focused insight and actionable protocol guidance.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-08

  This study presents a robust patient-derived gastric cancer assembloid model integrating matched tumor organoids with stromal cell subpopulations, effectively capturing tumor microenvironment complexity. The model reveals stromal influence on drug response and resistance, enabling improved preclinical drug screening and personalized therapy optimization.

• Deciphering In Vitro Drug Response Metrics in Cancer Researc

  2026-05-07

  Schwartz (2022) rigorously dissects how proliferative arrest and cell death are measured in anti-cancer drug evaluation, demonstrating that conventional metrics can conflate distinct biological outcomes. This work prompts a more nuanced interpretation of in vitro drug efficacy, with direct implications for selecting and benchmarking HDAC inhibitors like Entinostat (MS-275) in cancer research.

16452 records 1/1097 page Next 12345 下5页 Last page